10-Q: DarioHealth Corp. Reports Q3 2024 Results, Revenue Growth Driven by Commercial Channel and Twill Acquisition

DarioHealth Corp. saw a significant increase in revenue for Q3 2024, driven by growth in its commercial channel and the acquisition of Twill, despite ongoing losses and concerns about its ability to continue as a going concern.

Summary

• DarioHealth Corp. reported a revenue increase of 111% for the three months ended September 30, 2024, reaching $7.423 million, compared to $3.518 million in the same period of 2023.
• For the nine months ended September 30, 2024, revenue increased by 16.1% to $19.436 million, compared to $16.736 million in the same period of 2023.
• The company's revenue growth was primarily driven by its commercial channel and the inclusion of Twill's revenue following its acquisition in the first quarter of 2024.
• The pro forma revenue for the nine months ended September 30, 2024, including Twill as if acquired at the beginning of the year, would have been $21.399 million.
• The company's net loss decreased by 21.6% to $12.330 million for the three months ended September 30, 2024, compared to a net loss of $15.732 million for the same period in 2023.
• The net loss for the nine months ended September 30, 2024, decreased by 26.6% to $33.115 million, compared to a net loss of $45.142 million for the same period in 2023.
• The company's gross profit for the three months ended September 30, 2024, was $3.877 million (52.2% of revenues), compared to $610,000 (17.3% of revenues) in the same period of 2023.
• Gross profit for the nine months ended September 30, 2024, was $9.065 million (46.6% of revenues), compared to $5.852 million (35% of revenues) in the same period of 2023.
• The company's cash and cash equivalents decreased to $15.547 million as of September 30, 2024, from $36.797 million on December 31, 2023.
• DarioHealth has an accumulated deficit of $378.082 million and a stockholders equity of $58.511 million as of September 30, 2024.
• The company has experienced recurring losses and negative cash flows since inception and used approximately $31.830 million of cash in operations for the nine months ended September 30, 2024.
• DarioHealth believes its current cash on hand will not be sufficient to fund its projected operating requirements for a period of one year from the issuance of these interim financial statements, raising substantial doubt about its ability to continue as a going concern.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there is strong revenue growth and strategic acquisitions, the company's financial instability, reliance on a major customer, and going concern issues raise significant concerns. The sentiment is cautiously negative due to the financial risks.

Positives

• Revenue growth was strong, driven by the commercial channel and the Twill acquisition.
• Gross profit margins improved significantly, indicating better profitability on sales.
• The integration of Twill's platform expands DarioHealth's capabilities and market reach.
• The company is focused on a multi-condition platform, addressing multiple chronic conditions.
• DarioHealth has a growing number of signed contracts, demonstrating market traction.
• The company continues to generate clinical publications, supporting the value of its solutions.
• The company has reduced its net loss compared to the same period last year.

Negatives

• The company has incurred recurring losses and negative cash flows since inception.
• There is substantial doubt about the company's ability to continue as a going concern.
• Cash and cash equivalents have decreased significantly from the end of 2023.
• The company is dependent on a major customer for a significant portion of its revenue.
• The company's principal executive offices are located in Israel, which is currently facing political and military instability.
• The company's stock price has been extremely volatile and may continue to be volatile.
• The company received a notice from Nasdaq for not complying with the minimum bid price requirement.

Risks

• The company's ability to continue as a going concern is in doubt due to recurring losses and negative cash flows.
• The company is heavily reliant on a major customer, and losing this customer could significantly impact revenue.
• Political, economic, and military instability in Israel could adversely affect the company's operations.
• The company's stock price is highly volatile and could lead to significant losses for investors.
• The company faces the risk of being delisted from Nasdaq if it does not regain compliance with the minimum bid price requirement.
• The company may not be able to obtain additional funding on acceptable terms, which could hinder its growth and development.
• The company's commercial insurance does not cover losses that may occur as a result of events associated with war and terrorism.

Future Outlook

The company expects to continue to generate losses for the foreseeable future and is dependent on raising additional funds to fund its operations. The company intends to fund its future operations through cash on hand, additional private and/or public offerings of debt or equity securities or a combination of the foregoing.

Management Comments

• We are revolutionizing how people with chronic conditions manage their health through the innovation of a new category of digital health: Digital Therapeutics as a Service (DTaaS).
• We believe that our innovative approach to digital therapeutics disrupts the traditional provider-centered system of healthcare delivery by offering user-centric care that is continuous, customized supportive of better overall health.
• Our solutions combine the power of technologies and behavior science to make better health accessible, affordable, and easy for all by solving for what people need, when and where they want it, with hyper-personalized care that is always connected to services, devices, and people and delivered continuously.
• Our solutions are proven to drive savings for health plans and employers by improving the health of their populations.

Industry Context

DarioHealth is operating in the growing digital therapeutics market, which is seeing increased adoption by health plans and employers. The company's focus on a multi-condition platform aligns with the trend of integrated care solutions. The acquisition of Twill is a strategic move to enhance its behavioral health offerings and expand its market reach.

Comparison to Industry Standards

• DarioHealth's revenue growth of 111% in Q3 2024 is significantly higher than the average growth rate of many established digital health companies, however, this is largely due to the acquisition of Twill.
• The company's gross profit margin of 52.2% in Q3 2024 is competitive with other digital health companies that have a mix of software and hardware sales.
• The company's net losses are higher than some of its peers, reflecting its growth stage and investments in acquisitions and platform development.
• The company's cash burn rate is a concern, as it is dependent on raising additional capital to fund its operations.
• Compared to companies like Livongo (now part of Teladoc), DarioHealth is still in an earlier stage of commercialization, but is showing strong growth potential.
• The integration of Twill's behavioral health platform is a strategic move to compete with companies like Omada Health and Virta Health, which also offer multi-condition solutions.

Stakeholder Impact

• Shareholders face significant risks due to the company's financial instability and potential delisting from Nasdaq.
• Employees have been impacted by the workforce reduction, with 78 employees being laid off.
• Customers may benefit from the expanded platform and integrated solutions, but the company's financial instability could impact its ability to deliver services.
• Creditors face increased risk due to the company's going concern issues and reliance on additional funding.

Next Steps

• The company intends to monitor the closing bid price of its common stock and consider available options to resolve its noncompliance with the Nasdaq minimum bid price requirement.
• The company will continue to integrate Twill's platform and expand its multi-condition offerings.
• The company will seek additional funding to support its operations and growth.

Key Dates

Keywords

Digital Therapeutics, Chronic Conditions, DarioHealth, Twill, Revenue Growth, Multi-Condition Platform, B2B2C, Healthcare, Financial Results, Acquisition, Behavioral Health, Diabetes, Hypertension, Weight Management, Musculoskeletal Health